{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:40:24Z","timestamp":1792474824621,"version":"4.5.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDT"],"published-print":{"date-parts":[[2026,10,16]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The Epidermal Growth Factor Receptor (EGFR) serves as a core target in\ntumor-targeted therapy. Mutations in EGFR frequently lead to resistance against clinical Tyrosine\nKinase Inhibitors (TKIs), underscoring the critical need to develop novel EGFR-targeting compounds\nfor overcoming drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study performed in silico virtual screening of candidate small-molecule compounds from\ndatabases based on the common pharmacophore features of seven clinically used EGFR-TKIs. The candidates\nwere subjected to in silico physicochemical, pharmacochemical, and toxicity evaluations, as well as\nin silico prediction of kinase inhibitory activity, leading to the identification of ZINC44136419 as a computationally\npredicted candidate. Computational cross-validation of target proteins was conducted, and\nEGFR was identified as the putative core target protein through enrichment, interaction network, and mutation\nfrequency analyses. Molecular docking of ZINC44136419 with wild-type and mutant EGFR was\nperformed in silico, using gefitinib as a control to compare docking scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A computationally predicted kinase inhibitor candidate, ZINC44136419, was obtained. In\nsilico analyses indicated that it exhibited the core pharmacophore features of EGFR-TKIs, was predicted\nto meet drug-likeness criteria, showed no predicted toxicity risks, was predicted to have high\nsynthetic feasibility, and was identified as possessing a structurally distinct scaffold (low Tanimoto\nsimilarity to known inhibitors). In silico analyses revealed predicted selective inhibitory activity\nagainst the tyrosine kinase family, with target protein enrichment analysis showing significant association\nwith protein kinase activity, suggesting EGFR as a putative core target protein with high mutation\nfrequency. Notably, ZINC44136419 exhibited a more favorable docking score toward mutant\nEGFR than toward wild-type EGFR in silico, as compared to gefitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>discussion:<\/jats:title>\n                    <jats:p>As a novel EGFR inhibitor, ZINC44136419 achieves highly selective inhibition of drug-resistant mutants through its unique structure, providing a lead compound with translational potential for overcoming EGFR-TKI resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>This study relies entirely on computational simulations, which carry inherent methodological\nlimitations. Nevertheless, the favorable druggability and favorable docking scores of this\ncompound toward mutant targets in silico may provide candidate molecules and theoretical foundations\nfor subsequent in vitro experimental validation, delivery system development, and the design of\nnovel agents against EGFR drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>As a computationally predicted EGFR-targeting compound, ZINC44136419 is predicted\nin silico to show preferential docking interactions with drug-resistant mutants through its structurally\ndistinct scaffold, representing a preliminary candidate with potential translational value for overcoming\nEGFR-TKI resistance, pending experimental validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113894501509463261008055141","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:21:08Z","timestamp":1792473668000},"source":"Crossref","is-referenced-by-count":0,"title":["Discovery and Mechanistic Investigation of a Novel Kinase Inhibitor Targeting EGFR Resistance Mutations"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2490-9708","authenticated-orcid":true,"given":"Lu","family":"Qi","sequence":"first","affiliation":[{"name":"Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China"},{"name":"Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China"},{"name":"Guangdong Provincial Key Laboratory of Molecular Oncologic Pathology, Guangzhou, 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China"},{"name":"Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China"},{"name":"Guangdong Provincial Key Laboratory of Molecular Oncologic Pathology, Guangzhou, 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9753-5372","authenticated-orcid":true,"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine, School of Public Health, Southern Medical University, Guangzhou, 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501509463261008055141","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/259591\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501509463261008055141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:21:09Z","timestamp":1792473669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/259591\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501509463261008055141","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,16]]}}}